ZBeats gains FDA 510(k) clearance for ZBPro Diagnostic v2.0, enabling up to 14‑day ECG analysis via wearable patches
Executive summary: ZBeats received FDA 510(k) clearance for ZBPro Diagnostic v2.0, allowing ECG analysis up to 14 days via wearable patches. The extended monitoring window addresses a gap in ambulatory cardiac diagnostics, potentially improving detection of intermittent arrhythmias and expanding the addressable market for wearable ECG solutions.
Who is involved: ZBeats Inc., the U.S. Food and Drug Administration (FDA), and prospective clinical users such as cardiology clinics and hospital monitoring units.
Likely next: The company will showcase the new capability at HRX 2026 in Atlanta and pursue commercial rollout, seeking reimbursement partnerships and integration with electronic health record systems.
On September 15, 2026, ZBeats announced that the U.S. FDA granted 510(k) clearance for its ZBPro Diagnostic v2.0 platform, which extends continuous ECG recording capability from the typical 24‑48‑hour window to up to 14 days using adhesive wearable patches. The clearance covers use with a variety of recording devices and positions the product for broader ambulatory cardiac monitoring markets. ZBeats plans to demonstrate the updated system at the HRX 2026 conference in Atlanta later this month.
What's next — scenarios
Base: Steady adoption in specialty clinics (50%)
Generates modest revenue growth (~5‑10% YoY) as clinics integrate the 14‑day patch for selected patients.
- Positive reimbursement guidance from Medicare by Q1 2027
- Publication of clinical validation study in Q4 2026
Upside: Wide‑scale rollout to primary care and telehealth (30%)
Drives rapid sales increase (>30% YoY) and attracts partnership offers from major health‑system vendors.
- FDA releases favorable real‑world evidence guidance in mid‑2027
- Major insurer announces coverage for >14‑day ECG monitoring
Downside: Limited uptake due to cost and reimbursement hurdles (20%)
Sales remain flat, prompting ZBeats to explore price reductions or niche veterinary applications.
- Medicare denies coverage extension beyond 7 days in late 2026
- Competitor launches a lower‑cost 14‑day patch in early 2027
What to watch
- Medicare coverage decision for extended ECG monitoring (expected Q1 2027)
- HRX 2026 conference presentation date (mid‑September 2026)
- Publication of peer‑reviewed clinical trial results (expected October 2026)
- Private insurer reimbursement announcements for >14‑day ECG monitoring (Q4 2026)
Timeline
- — ZBeats Receives FDA Clearance for ZBPro Diagnostic v2.0, Supporting ECG Analysis Up to 14 Days (PR Newswire)
Analysis — what this means
Likely next events
- ZBeats to showcase ZBPro Diagnostic v2.0 at HRX 2026 in Atlanta (mid‑September 2026)
Sectors affected
- wearable ECG diagnostics
- ambulatory cardiac monitoring
Regulatory implications
- FDA 510(k) clearance requires post‑market surveillance reporting and adherence to special controls for ECG analysis software.
Key entities
Sources
- ZBeats Receives FDA Clearance for ZBPro Diagnostic v2.0, Supporting ECG Analysis Up to 14 Days — PR Newswire
Related cases
- IASO Bio secures FDA clearance for first China-origin lentiviral in vivo CAR-T therapy
- Capricor Therapeutics faces growing legal pressure as investors approach deadline for class action leadership amidst FDA review uncertainties
- Outlook Therapeutics focuses on commercializing LYTENAVA following FDA regulatory milestones
- Prelude Therapeutics advances toward clinical trials for first-in-class oral KAT6A degrader following FDA IND clearance
- CraniUS Therapeutics secures FDA 510(k) clearance for its patient-specific cranial implant platform
- Opus Genetics advances OPGx-BEST1 toward Phase 3 after positive low-dose clinical data and successful FDA alignment